Analysts Issue Forecasts for GH Research PLC’s Q1 2025 Earnings (NASDAQ:GHRS)

GH Research PLC (NASDAQ:GHRS) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of GH Research in a research note issued to investors on Wednesday, July 31st. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of ($0.21) for the quarter. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.84) per share. HC Wainwright also issued estimates for GH Research’s Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.22) EPS and Q4 2025 earnings at ($0.20) EPS.

Separately, Canaccord Genuity Group boosted their price target on GH Research from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, May 6th.

GH Research Price Performance

Shares of NASDAQ:GHRS opened at $12.33 on Friday. GH Research has a 1-year low of $5.05 and a 1-year high of $14.99. The business’s 50 day moving average is $12.23 and its 200-day moving average is $10.59.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings data on Friday, May 3rd. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.07.

Institutional Trading of GH Research

Several institutional investors have recently bought and sold shares of the stock. BVF Inc. IL raised its position in GH Research by 12.1% in the 4th quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock valued at $60,321,000 after purchasing an additional 1,125,000 shares during the last quarter. RA Capital Management L.P. raised its position in GH Research by 11.9% in the 1st quarter. RA Capital Management L.P. now owns 6,251,714 shares of the company’s stock valued at $66,643,000 after purchasing an additional 664,381 shares during the last quarter. Lynx1 Capital Management LP raised its position in GH Research by 80.1% in the 1st quarter. Lynx1 Capital Management LP now owns 3,310,563 shares of the company’s stock valued at $35,291,000 after purchasing an additional 1,471,946 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in GH Research by 14.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 106,363 shares of the company’s stock valued at $617,000 after purchasing an additional 13,579 shares during the last quarter. Finally, AdvisorShares Investments LLC raised its position in GH Research by 4.3% in the 4th quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock valued at $280,000 after purchasing an additional 1,977 shares during the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).